摘要
目的:评价奥氮平治疗难治性精神分裂症的疗效及安全性。方法:将68例难治性精神分裂症患者随机分为研究组和对照组,分别给予奥氮平和氯氮平治疗12周,用阳性和阴性症状量表(PANSS)、临床总体印象量表(CGI)评定临床疗效,用副反应量表(TESS)、锥体外系副反应量表(RSESE)评定不良反应。结果:治疗前两组阳性与阴性症状量表各项得分无显著差异(P>0.05);治疗后两组总有效率无显著性差异(P>0.05);认知因子和阴性症状减分率,两组间有显著性差异(P<0.05);奥氮平的不良反应较氯氮平轻。结论:奥氮平对难治性精神分裂症疗效肯定,不良反应较轻,特别是在改善认知功能和阴性症状方面有较好的效果。
Objective： To evaluate the efficacy and safety of Olanzapine in the treatment of treatment - resistant schizophrenia. Methods：A total of 68 patients with treatment -resistant schizophrenia were randomly assigned to the Olanzapine group and the Clozapine group for 12 weeks of treatment. The efficacy was evaluated with Positive and Negative Symptom scale （PANSS） and Clinical Global Impression （CGI）, and the side effects were evaluated with treatment emergent symptoms scale （TESS） and Rating Scale for Extra pyramidal Side Effects （RSESE）. Results： There were no significant differences in scores of the PANSS before treatment and in total effective rates after treatment between the two groups （ both P 〉 0. 05 ） ; there were significant differences in cognitive factor and score - reducing rates of negative symptoms （ P 〈 0.05 ）. The side effects of Olanzapine were milder than that of Clozapine. Conclusions： Olanzapine is effective and has milder side effects in the treatment of refractory schizophrenia, especially in improving cognitive function and negative symptoms.
出处
《中国民康医学》
2009年第23期2955-2956,2960,共3页
Medical Journal of Chinese People’s Health
关键词
奥氮平
氯氮平
难治性精神分裂症
Olanzapine
Clozapine
Treatment - resistant schizophrenia
